Delenex's DLX105 misses in psoriasis Phase II

Delenex Therapeutics AG (Zurich, Switzerland) said DLX105 led to no

Read the full 109 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE